Header

UZH-Logo

Maintenance Infos

A review of the value of innovation in inhalers for COPD and asthma


Virchow, Johann Christian; Akdis, Cezmi A; Darba, Josep; Dekhuijzen, Richard; Hartl, Sylvia; Kobelt, Gisela; Roger, Albert; Simoens, Steven; Toumi, Mondher; Woodhouse, Ben; Plich, Adam; Torvinen, Saku (2015). A review of the value of innovation in inhalers for COPD and asthma. Journal of Market Access & Health Policy, 3:28760.

Abstract

Background: Appropriate use of inhaled therapies for asthma and chronic obstructive pulmonary disease (COPD) is critical to ensuring good patient outcomes, efficient use of healthcare resources and limiting the effects of high-morbidity. The appropriate choice of inhaler and active therapy, incorporating patient preferences, can help improve treatment adherence and long-term outcomes. Despite this, many current inhalers are non-intuitive to use, and require extensive training. Methods: In this review, an expert panel considers the evidence for the use of inhaler devices in management of COPD and asthma. The panel also evaluates the value of innovation in inhaler technologies, which optimise the use of existing molecules from a clinical, economic and societal perspective. Conclusions: The panel conclusion is that there remains a substantial unmet need in inhaler technology and that innovation in inhaler devices can provide real-world health benefits to patients. Furthermore, we recommend that these innovations should be supported by healthcare systems through appropriate pricing and reimbursement mechanisms. Keywords: Asthma; Chronic obstructive pulmonary disease; innovation; patient preference; adherence; patient compliance; metered dose inhaler; dry powder inhaler; medication errors; value

Abstract

Background: Appropriate use of inhaled therapies for asthma and chronic obstructive pulmonary disease (COPD) is critical to ensuring good patient outcomes, efficient use of healthcare resources and limiting the effects of high-morbidity. The appropriate choice of inhaler and active therapy, incorporating patient preferences, can help improve treatment adherence and long-term outcomes. Despite this, many current inhalers are non-intuitive to use, and require extensive training. Methods: In this review, an expert panel considers the evidence for the use of inhaler devices in management of COPD and asthma. The panel also evaluates the value of innovation in inhaler technologies, which optimise the use of existing molecules from a clinical, economic and societal perspective. Conclusions: The panel conclusion is that there remains a substantial unmet need in inhaler technology and that innovation in inhaler devices can provide real-world health benefits to patients. Furthermore, we recommend that these innovations should be supported by healthcare systems through appropriate pricing and reimbursement mechanisms. Keywords: Asthma; Chronic obstructive pulmonary disease; innovation; patient preference; adherence; patient compliance; metered dose inhaler; dry powder inhaler; medication errors; value

Statistics

Altmetrics

Downloads

17 downloads since deposited on 12 Jan 2016
9 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > Swiss Institute of Allergy and Asthma Research
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:Asthma; Chronic obstructive pulmonary disease; innovation; patient preference; adherence; patient compliance; metered dose inhaler; dry powder inhaler; medication errors; value
Language:English
Date:2015
Deposited On:12 Jan 2016 14:03
Last Modified:02 Jun 2017 02:14
Publisher:Co-Action Publishing
ISSN:2001-6689
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.3402/jmahp.v3.28760

Download

Download PDF  'A review of the value of innovation in inhalers for COPD and asthma'.
Preview
Content: Published Version
Filetype: PDF
Size: 341kB
View at publisher
Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)